NovoCure Files 8-K on Financials
Ticker: NVCR · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1645113
| Field | Detail |
|---|---|
| Company | Novocure Ltd (NVCR) |
| Form Type | 8-K |
| Filed Date | Jan 13, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-k, operations
TL;DR
NovoCure dropped its 8-K detailing financial results for Jan 2025.
AI Summary
NovoCure Limited filed an 8-K on January 13, 2025, reporting on its financial condition and results of operations. The filing includes financial statements and exhibits, with the report period covering January 1, 2025, to January 31, 2025. NovoCure Limited is incorporated in Jersey and operates in the surgical and medical instruments sector.
Why It Matters
This 8-K filing provides investors with crucial updates on NovoCure's financial performance and operational status, impacting investment decisions.
Risk Assessment
Risk Level: low — This is a routine financial filing and does not indicate any immediate or significant risks.
Key Players & Entities
- NovoCure Limited (company) — Registrant
- January 13, 2025 (date) — Filing Date
- January 1, 2025 (date) — Report Period Start Date
- January 31, 2025 (date) — Report Period End Date
- Jersey (location) — Jurisdiction of Incorporation
FAQ
What is the primary purpose of this 8-K filing by NovoCure Limited?
The primary purpose is to report on NovoCure Limited's Results of Operations and Financial Condition, including financial statements and exhibits.
On what date was this 8-K filed with the SEC?
This 8-K was filed on January 13, 2025.
What is the reporting period covered by this 8-K?
The reporting period covered is from January 1, 2025, to January 31, 2025.
In which jurisdiction is NovoCure Limited incorporated?
NovoCure Limited is incorporated in Jersey.
What is NovoCure's Standard Industrial Classification (SIC) code and industry?
NovoCure's SIC code is 3841, which corresponds to Surgical & Medical Instruments & Apparatus.
Filing Stats: 639 words · 3 min read · ~2 pages · Grade level 12.2 · Accepted 2025-01-13 07:00:33
Filing Documents
- nvcr-20250113.htm (8-K) — 26KB
- pr_jpmq42024pre-announceme.htm (EX-99.1) — 41KB
- 0001645113-25-000001.txt ( ) — 198KB
- nvcr-20250113.xsd (EX-101.SCH) — 2KB
- nvcr-20250113_lab.xml (EX-101.LAB) — 21KB
- nvcr-20250113_pre.xml (EX-101.PRE) — 12KB
- nvcr-20250113_htm.xml (XML) — 3KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On January 13, 2025 , NovoCure Limited ( the "Company") issued a press release announcing certain preliminary financial results and providing certain other information for the quarter and year ended December 31, 2024. A copy of the press release is attached hereto as Exhibit 99.1 (the "Press Release"). The financial data contained therein are unaudited, preliminary, based upon the Company's good faith estimates and subject to completion of the Company's financial closing procedures. While the Company expects that its final financial results for the quarter and year ended December 31, 2024, following the completion of its financial closing procedures, will generally be consistent with the information provided in the Press Release, the Company's actual results may differ materially from these estimates as a result of the completion of its financial closing procedures for the quarter and year ended December 31, 2024, as well as final adjustments and other developments that may arise between now and the time that its financial results for the quarter and year ended December 31, 2024 are finalized. The information contained in item 2.02 of this Current Report shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release of NovoCure Limited, dated January 13, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NovoCure Limited (Registrant) Date: January 13, 2025 By: /s/ Christoph Brackmann Name: Christoph Brackmann Title: Chief Financial Officer